https://www.selleckchem.com/pr....oducts/gsk3368715.ht
The effectiveness of cisplatin, a mainstay in treatment of many solid organ cancers, is hindered by dose-limiting nephrotoxicity. Cisplatin causes acute kidney injury (AKI) in 30% of patients. Patients who do not develop AKI by clinical standards during the course of treatment are still at risk for long-term decline in kidney function and the development of chronic kidney disease (CKD). The connection between AKI and CKD has become increasingly studied, with renal fibrosis being a hallmark of CKD development. To prevent both the shor
Like
Comment
Share
